Evidence map›Paper›PMID 38538718›Full record

ArticleActa pharmacologica Sinica2024

Radiofrequency radiation reshapes tumor immune microenvironment into antitumor phenotype in pulmonary metastatic melanoma by inducing active transformation of tumor-infiltrating CD8

Jia-Zheng Jiao, Yang Zhang, Wen-Juan Zhang, Min-di He, Meng Meng, Tao Liu, Qin-Long Ma, Ya Xu, Peng Gao, Chun-Hai Chen and 8 more

Open access · hybridAbstract read
In one paragraph

Article in Acta pharmacologica Sinica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 1 country.

Jia-Zheng Jiao *Key Laboratory for Electromagnetic Radiation Medical Protection of Ministry of Education, Army Medical University, Chongqing, 400038, China.
Yang Zhang *Radiation Biology Center, Chongqing University Cancer Hospital, Chongqing, 400030, China.
Wen-Juan ZhangKey Laboratory for Electromagnetic Radiation Medical Protection of Ministry of Education, Army Medical University, Chongqing, 400038, China.
Min-di HeKey Laboratory for Electromagnetic Radiation Medical Protection of Ministry of Education, Army Medical University, Chongqing, 400038, China.
Meng MengDepartment of Clinical Hematology, College of Pharmacy and Laboratory Medicine, Army Medical University, Chongqing, 400038, China.
Tao LiuDepartment of Clinical Hematology, College of Pharmacy and Laboratory Medicine, Army Medical University, Chongqing, 400038, China.
Qin-Long MaKey Laboratory for Electromagnetic Radiation Medical Protection of Ministry of Education, Army Medical University, Chongqing, 400038, China.
Ya XuRadiation Biology Center, Chongqing University Cancer Hospital, Chongqing, 400030, China.
Peng GaoKey Laboratory for Electromagnetic Radiation Medical Protection of Ministry of Education, Army Medical University, Chongqing, 400038, China.
Chun-Hai ChenKey Laboratory for Electromagnetic Radiation Medical Protection of Ministry of Education, Army Medical University, Chongqing, 400038, China.
Lei ZhangKey Laboratory for Electromagnetic Radiation Medical Protection of Ministry of Education, Army Medical University, Chongqing, 400038, China.
Hui-Feng PiKey Laboratory for Electromagnetic Radiation Medical Protection of Ministry of Education, Army Medical University, Chongqing, 400038, China.
Ping DengKey Laboratory for Electromagnetic Radiation Medical Protection of Ministry of Education, Army Medical University, Chongqing, 400038, China.
Yong-Zhong WuRadiation Oncology Center, Chongqing University Cancer Hospital, Chongqing, 400030, China.
Zhou ZhouCenter for Neurointelligence, School of Medicine, Chongqing University, Chongqing, 400030, China.
Zheng-Ping YuKey Laboratory for Electromagnetic Radiation Medical Protection of Ministry of Education, Army Medical University, Chongqing, 400038, China. yuzping_tmmu@126.com.
You-Cai DengDepartment of Clinical Hematology, College of Pharmacy and Laboratory Medicine, Army Medical University, Chongqing, 400038, China. youcai.deng@tmmu.edu.cn.
Yong-Hui LuKey Laboratory for Electromagnetic Radiation Medical Protection of Ministry of Education, Army Medical University, Chongqing, 400038, China. everlightlu@163.com.
Army Medical University · CNChongqing Cancer Hospital · CNChongqing University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunosuppression by the tumor microenvironment is a pivotal factor contributing to tumor progression and immunotherapy resistance. Priming the tumor immune microenvironment (TIME) has emerged as a promising strategy for improving the efficacy of cancer immunotherapy. In this study we investigated the effects of noninvasive radiofrequency radiation (RFR) exposure on tumor progression and TIME phenotype, as well as the antitumor potential of PD-1 blockage in a model of pulmonary metastatic melanoma (PMM). Mouse model of PMM was established by tail vein injection of B16F10 cells. From day 3 after injection, the mice were exposed to RFR at an average specific absorption rate of 9.7 W/kg for 1 h per day for 14 days. After RFR exposure, lung tissues were harvested and RNAs were extracted for transcriptome sequencing; PMM-infiltrating immune cells were isolated for single-cell RNA-seq analysis. We showed that RFR exposure significantly impeded PMM progression accompanied by remodeled TIME of PMM via altering the proportion and transcription profile of tumor-infiltrating immune cells. RFR exposure increased the activation and cytotoxicity signatures of tumor-infiltrating CD8

Indexed as

CD8-Positive T-LymphocytesKiller Cells, NaturalLung NeoplasmsMice, Inbred C57BLTumor MicroenvironmentAnimalsImmune Checkpoint InhibitorsLymphocytes, Tumor-InfiltratingMelanoma, ExperimentalMicePhenotypeProgrammed Cell Death 1 ReceptorImmune Checkpoint InhibitorsProgrammed Cell Death 1 Receptorcancer immunotherapyCD8+ T cellsNK cellspulmonary metastatic melanomaradiofrequency radiationtumor immune microenvironment

Identifiers

PMID38538718
PMCPMC11192955
OpenAlexW4393227997

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.